Ratio Therapeutics Inc.
PrivateLast Round
Series C
Jul 31, 2026
Total Funding Raised
$90M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Ratio Therapeutics Inc. is a biotechnology company that develops next-generation precision radiopharmaceuticals for the treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials, Pharma Supply Chain
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ratio Therapeutics Inc. Comparables
Compare Ratio Therapeutics Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ARTBIO | 92% | |
| Aktis Oncology | 89% | |
| Actithera | 87% |
Ratio Therapeutics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 31, 2026 | ||||
| Series B | Jan 17, 2024 | ||||
| Series A | Feb 1, 2023 | ||||
| Seed | Jun 10, 2022 |
Ratio Therapeutics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Center for Technology Licensing at Cornell University | Series B |
| Duquesne Family Office | Series C, Series A |
| Pags Group | Series B |
| Charles and Lynn Schusterman Family Philanthropies | Series A |
| Schusterman Family Investments | Series A, Series B |
| Catalio Capital Management | Series A, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 55% MoM, reaching 6.1K.
- Jul 31, 2026
$70M round with participation from Catalio Capital Management and Duquesne Family Office.
Recent news
Latest coverage and updates
- partners_withSep 9, 2026
Ratio Therapeutics partnered with RayzeBio, Inc. on Sep 9th '26.
- receives_financingAug 3, 2026
Ratio Therapeutics received financing of $70M in Series C on Aug 3rd '26.
Ratio Therapeutics Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ratio Therapeutics Inc.'s valuation, stock price, and market status.
Is Ratio Therapeutics Inc. a public or private company?
Ratio Therapeutics Inc. is a private company.
What is the current stock price of Ratio Therapeutics Inc.?
Ratio Therapeutics Inc. is a private company, so its shares have no public market price. Caplight tracks Ratio Therapeutics Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ratio Therapeutics Inc. worth (valuation)?
Valuation information for Ratio Therapeutics Inc. is not publicly available.
Can I buy Ratio Therapeutics Inc. stock?
Ratio Therapeutics Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ratio Therapeutics Inc.'s last funding round?
Ratio Therapeutics Inc.'s most recent funding round was Series C on July 31, 2026.
Who are the main investors in Ratio Therapeutics Inc.?
Key investors in Ratio Therapeutics Inc. include Duquesne Family Office, Charles and Lynn Schusterman Family Philanthropies, Schusterman Family Investments.
Will Ratio Therapeutics Inc. IPO soon?
No public IPO plans have been announced for Ratio Therapeutics Inc..
How can I track Ratio Therapeutics Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Ratio Therapeutics Inc.'s shares on secondary markets.